Anti-CD19 Monoclonal antibody, clone 2E4 [eFluor® 660]

Background X-linked agammaglobulinaemia (XLA) is a rare immunodeficiency disease for which recurrent severe infection is the major clinical symptom.BTKis the main causative gene, with X chromosome recessive inheritance. However, the mutations reported to date do not fully explain the disorder. Methods We detected the percentage of CD19+ B cells and serum immunoglobulin (IgG, IgA, and IgM) levels by flow cytometry and rate scatter immunoturbidimetry, and investigated theBTKmutation profile in 22 XLA patients using Sanger sequencing and real-time PCR . Results We evaluated the clinical symptoms of 22 XLA patients and investigated genetic mutations present, identifying six novel mutations in theBTKgene: 2 missense mutations (c.23G > T and c.112 T > C), 2 frameshift mutations (c.522_523insC and c.1060delA), 1 large deletion (deletion of exon 2 to 5), and 1 splice-site mutation (c.1631 + 2 T > C). Prenatal diagnoses were performed in six families (F10, F11, F15, F18, F20 and F21), with the following results: the male fetus in Family 10 (F10) did not carry the c.922_923delGA mutation; the male fetus in Family 15 (F15) did not carry the c.1631 + 1G > T splicing mutation; the female fetus in Family 20 (F20) did not carry the c.1931 T > C mutation; the female fetus in Family 21 (F21) did not carry the large deletion mutation. Hence, these four fetuses are not likely to develop XLA. Male fetuses with c.1060delA and c.1684C > T mutations were identified in Family 11 and Family 18, respectively. The pregnant woman in F18 chose to terminate the pregnancy, whereas the pregnant woman in F11 chose to continue the pregnancy. Conclusion We confirmed the diagnosis of 22 XLA patients from 22 unrelated families and detected six new pathogenic mutations. Prenatal diagnosis was performed in six families. Early genetic diagnosis and routine lifelong immunoglobulin replacement therapy can prevent and treat infections in XLA children, saving their lives.

The utilization of live cells as therapeutic materials provides controllability and complexity unmatched by small molecules and biologic agents. Recent advancements have shown that the manipulation of live cells can allow the development of powerful tools for the diagnosis of disease, production of biologics, and application as therapeutics. The field of cellular engineering has rapidly evolved and advanced to provide immuno-oncological relief through various genetic circuits and targeting motifs. In utilizing living materials comprised of cells, complex reactions and responsive elements can be created to generate novel controllable systems. This review discusses the general principles of cellular engineering in the clinical space and highlights its utilization in chimeric antigen receptor (CAR) T-cell therapy. In particular, the review focuses on the control systems implemented on CAR T-cells to mitigate adverse effects and increase the potency of therapy.